ACPU
ACHN

Arrowgrass Capital Partners (US)’s Achillion Pharmaceuticals ACHN Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,307,900
Closed -$3.95M – 213
2013
Q3 		$3.95M Buy
+1,307,900
New +$8.97M 0.15% 115

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s ACHN Position: Q1 2014 in Review

Arrowgrass Capital Partners (US) sold out of Achillion Pharmaceuticals (ACHN) in Q1 2014, closing a stake of 275,000 shares — an estimated $913K sold.

Arrowgrass Capital Partners (US) first reported a position in ACHN in Q3 2013 and held it in 2 quarters. The position peaked at $3.4M in Q3 2013. 94 funds tracked by Wall St. Rank hold ACHN as of Q1 2014.

  • Arrowgrass Capital Partners (US) reported no remaining Achillion Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 275,000 Achillion Pharmaceuticals shares in Q1 2014, an estimated $913K.
  • Arrowgrass Capital Partners (US) first reported a position in Achillion Pharmaceuticals in Q3 2013 and held it in 2 quarters.
  • Arrowgrass Capital Partners (US)'s Achillion Pharmaceuticals position peaked at $3.4M in Q3 2013.
  • 94 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2014.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q1 2014, filed 15 May 2014.